Navigation Links
GeneThera Extends its Reach Overseas
Date:6/16/2009

Results from Pharma Finance 2009

ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC: GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is addressing our recent events.

GeneThera Inc. recently attended Pharma Finance 2009, a Biotechnology, Medical Devices, and world public and private Finance Conference in Rome, Italy on June 4-5.

Pharma Finance is an international event addressing new technologies for Life Sciences, concentrating on Biotechnology, finance, nano-technology and innovative materials.

The Lazio Region and Sviluppo Lazio S.p.A. jointly organized Pharma Finance, in collaboration with the Ministry for International Commerce, ICE, Filas S.p.A. and the Zangani Investor Community.

During the two-day event big pharma, small and medium size enterprises, research and university centers presented their products, research projects and technologies. The Conference foreign delegation session fostered the internationalization process taken by many businesses, to develop international cooperation; the presence of Business Angels and Venture Capitalist provided useful information to new entrepreneurial activities.

Dr. Milici comments, "We felt that this particular conference provided us the opportunity to meet with companies outside the United States, such as Canada and Italy, but also emerging nations such as The United Arab Emirates and Singapore to name a few. We feel that the safety of the world's food system can be protected by our proprietary technology, which stems from our vast expertise in creating solutions from microbiology and genetics."

As a result of the attendance at Pharma Finance 2009, GeneThera is in talks with the University of Rome, who is also working on a vaccine for Johne's disease and looking to collaborate on the activities in Mexico. In addition, GeneThera will be looking to expand its investor base by applying for the TSX Venture Exchange after speaking with the exchange's vice president.

As discussions progress, the company will release more details.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Arvada, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Richard Dopkin at JR Dopkin & Associates LLC at 516-884-3200.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
2. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
3. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
4. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
5. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
6. BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
11. Ziehm Imaging Extends its Training Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... ... The AMA is happy to announce that $48,000 in scholarships will be awarded ... created through funds donated by model aviation organizations and individuals, AMA members, and a ... Committee, which is made up of model aviation pilots and enthusiasts. The committee evaluates ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology ... of emerging technology-based businesses, recently earned a $77,518 grant from the Rural Maryland ... in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is a ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... their strategic partnership to offer a full spectrum of digital security goods and ... of biometric products and the ground-breaking proactive cybersecurity services and products through Assured ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):